Sterile Injectable Drugs Market, By Type (Small Molecule and Large Molecule), By Therapeutic Application (Cancer, Diabetes, Cardiovascular Diseases, Infectious Disorders, Central Nervous Systems, Musculoskeletal, Anti-Viral, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Trends, Analysis and Forecast till 2034

Sterile injectable drugs market was valued at US$ 706.9 Billion in 2024 and is projected to grow at a CAGR of 4.70% to reach US$ 1077.1 Billion by 2034.

The Sterile Injectable Drugs molecule is known as active substances. They are divided into two class, large and small molecule as they differ in the manufacturing process, size, and mode of action in the body. Small molecules are mostly chemically manufactured active-substance molecules while large molecule, also known as biologics are therapeutic proteins. They are composed of more than 1,300 amino acids. Moreover, the large molecule is produced through genetically modified cells of microorganisms such as bacteria and yeast.

Drivers and Restraints:

Increasing in the prevalence of chronic diseases such as cardiovascular disease, diabetes is a major factor driving the growth of the global sterile injectable market globally. According to data published by the National Institute of Cancer, in 2016, about 1,685,210 new cancer cases are likely to be diagnosed in the U.S. and 5,95,690 patients will surrender to the disease. Also, growing investment in R&D by major pharmaceutical players for developing disease-specific drugs is projected to boost the growth of the global market over the forecast period. Furthermore, the rising number for drug approvals by the health authority for injectable and subsequently successful commercialization and launching of innovative drugs is anticipated to further propel the growth of the global market over the forecast period. However, manufacturing of sterile injectable involves the high cost of equipment, packaging, storage, and distribution which in turn hampers the growth of the target market. Nevertheless, various companies are focusing on developing innovative drugs that can absorb in the body quickly providing a quick therapeutic response, will create lucrative opportunities for major players in the global sterile injectable market over the forecast period.

Segmentation:

The  sterile injectable drugs market is segmented based on type, therapeutic application, distribution channel, and region.

Based on type, the global sterile injectable drugs market is segmented into small molecule and large molecule. Based on therapeutic application, the global market is segmented into cancer, diabetes, cardiovascular diseases, infectious disorders, central nervous systems, musculoskeletal, anti-viral, and others. Based on the distribution channel, the target market is classified into hospital pharmacies, retail pharmacies, and online pharmacies. Hospital pharmacies distribution channel segment is projected to dominate the market in the future, due to the major patient population in hospitals.

On the region, the global sterile injectable drugs market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The Asia Pacific is accounted to register the highest rate of growth in the sterile injectable drugs market. This is mainly attributed due to the presence of a large patient pool, rising awareness about sterile injectable drugs, presence of various small pharma companies in India and China, and the introduction of different types of policies by various government bodies. North America is estimated to lead the market for sterile injectable drugs over the forecast period, due to the presence of major players in the region, rapid developments made in healthcare infrastructure, and huge investments made in the research and development. The rise in the prevalence of chronic diseases, increase in investment witnessed across the healthcare sector, and the enforcement of strict government regulations for sterile injectable drugs, is likely to boost this market in the European region.

Key Players:

The key players operating the global sterile injectable drugs market involves AstraZeneca plc., Novartis AG, Baxter International Inc., Johnson & Johnson, Sanofi S.A., Pfizer Inc., GlaxoSmithKline plc., Gilead Sciences, Inc., Merck & Co., Inc., and Nova Nordisk A/S. Prominent players operating in the target market are focusing on strategic partnerships as well as the launching of the types to gain a competitive edge in the target market. For instance, on 6^th January 2020, AstraZeneca announced the U.S Food and Drug Administration (FDA) has established a supplemental New Drug Application (sNDA) and granted Priority Review for Farxiga (dapagliflozin). To reduce the risk of cardiovascular (CV) death or the worsening of heart failure (HF) in adults with heart failure with reduced ejection fraction (HFrEF) with and without type-2 diabetes (T2D).

Detailed Segmentation:

Sterile Injectable Drugs Market, By Type:

• Small Molecule
• Large Molecule

Sterile Injectable Drugs Market, By Therapeutic Application:

• Cancer
• Diabetes
• Cardiovascular Diseases
• Infectious Disorders
• Central Nervous Systems
• Musculoskeletal
• Anti-Viral
• Others

Sterile Injectable Drugs Market, By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Sterile Injectable Drugs Market, By Region:

• North America
  • Middle East & Africa
    • Middle East & Africa Sterile Injectable Drugs Market, By Type
    • Middle East & Africa Sterile Injectable Drugs Market, By Therapeutic Application
    • Middle East & Africa Sterile Injectable Drugs Market, By Distribution Channel
    • Middle East & Africa Sterile Injectable Drugs Market, By Country
      • GCC
      • Israel
      • South Africa
      • Rest of Middle East & Africa
  • Latin America
    • Latin America Sterile Injectable Drugs Market, By Type
    • Latin America Sterile Injectable Drugs Market, By Therapeutic Application
    • Latin America Sterile Injectable Drugs Market, By Distribution Channel
    • Latin America Sterile Injectable Drugs Market, By Country
      • Brazil
      • Mexico
      • Rest of Latin America
  • Asia Pacific
    • Asia Pacific Sterile Injectable Drugs Market, By Type
    • Asia Pacific Sterile Injectable Drugs Market, By Therapeutic Application
    • Asia Pacific Sterile Injectable Drugs Market, By Distribution Channel
    • Asia Pacific Sterile Injectable Drugs Market, By Country
      • China
      • India
      • Japan
      • South Korea
      • Rest of Asia Pacific                                                                                                                                                                                     
  • Europe
    • Europe Sterile Injectable Drugs Market, By Type
    • Europe Sterile Injectable Drugs Market, By Therapeutic Application
    • Europe Sterile Injectable Drugs Market, By Distribution Channel
    • Europe Sterile Injectable Drugs Market, By Country
      • Germany
      • UK
      • France
      • Russia
      • Italy
      • Rest of Europe
  • North America Sterile Injectable Drugs Market, By Type
  • North America Sterile Injectable Drugs Market, By Therapeutic Application
  • North America Sterile Injectable Drugs Market, By Distribution Channel
  • North America Sterile Injectable Drugs Market, By Country
    • U.S.
    • Canada

Company Profile:

• AstraZeneca plc.
  • Company Overview

• Product Portfolio
  • Key Highlights
  • Financial Performance
• Baxter International, Inc.
• Novartis AG
• Johnson & Johnson
• Merck & Co., Inc.
• Sanofi S.A.
• Pfizer, Inc.
• GlaxoSmithKline plc.
• Gilead Sciences, Inc.
• Nova Nordisk A/S.

 “*” marked represents similar segmentation in other categories in the respective section